Company intelligence / Profile preview
ImmuneOnco
Shanghai, Shanghai, Chinaimmuneonco.com ↗
- Ownership
- Public · 01541.HK
- Employees
- ~250
- Development stage
- Phase 3
01
Overview
ImmuneOnco has advanced its lead program timdarpacept (IMM01), an SIRPα-IgG1 Fc fusion protein for higher-risk MDS/CMML/cHL into phase III trials. Its next most advanced asset is amulirafusp alfa (IMM0306), a CD20xCD47 bispecific with strong efficacy signals in follicular lymphoma when combined with lenalidomide—achieving a reported ORR of up to 91%, CRR of 27%, as well as promising early data in SLE. The company’s broad pipeline includes several other first-in-class or best-in-class immunotherapies at various stages of development. Key collaborations include global licensing deals outside Greater China worth over $2 billion with Instil Bio for two major assets.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Monoclonal antibodyBispecific monoclonal antibodyFusion proteinAntibody-drug conjugateSmall moleculeRecombinant fusion protein
- Industry
- Biotech
02
Drug pipeline
19 assets18 more assets in the full pipeline.
03
Partnerships
Instil Bio – global development/commercialization partnership outside Greater China for key assets including VEGFxPD-L1 bispecific and anti‑CTLA-4 mAb (>USD $2B deal value)
04
Financials
- Market cap
- $149.9M
- Total revenue
- $22.5M
- Enterprise value
- $62.5M
Beyond the preview
Go deeper on ImmuneOnco.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ImmuneOnco.